Breaking Finance News

TheStreet downgraded Teladoc Inc (NYSE:TDOC) to D in a report released today.

TheStreet has downgraded Teladoc Inc (NYSE:TDOC) to D in a report released on Monday July 03, 2017.

Previously on 6/20/2017, Canaccord Genuity reported about Teladoc Inc (NYSE:TDOC) raised the target price from $34.00 to $42.00. At the time, this indicated a possible upside of 0.31%.

Yesterday Teladoc Inc (NYSE:TDOC) traded -1.14% lower at $34.50. The company’s 50-day moving average is $33.88 and its 200-day moving average is $27.52. The last stock close price is up 10.28% from the 200-day moving average, compared to the S&P 500 which has increased 0.05% over the same time. 682,680 shares of the stock were exchanged, down from an average trading volume of 1,004,110

See Chart Below

Teladoc Inc (NYSE:TDOC)

Teladoc Inc has a 52 week low of $14.00 and a 52 week high of $36.90 TDOC’s total market value is presently $0.

Brief Synopsis About Teladoc Inc (NYSE:TDOC)

Teladoc, Inc. is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company's solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation. As of July 17, 2017, it served over 7,500 employers, health plans, health systems and other entities. As of July 17, 2017, these clients collectively purchased access to its solution for more than 20 million Members. As of December 31, 2016, it had over 30 health plans as Clients. Its solutions consist of an integrated technology platform, Provider network, consumer engagement strategies and entrenched distribution channels.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.